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ABSTRACT 
Objective: The objective of the present research work is to develop compression coated tablet of ketoprofen as a pulsatile release system for 
treatment of rheumatoid arthritis.  
Methods: Core tablets of ketoprofen were prepared using the wet granulation method and evaluated for appearance, hardness, friability, weight 
variation, thickness, disintegration time and % drug release. Core tablets were coated with Eudragit S100 and Eudragit L100 by compression 
coating method to achieve desired lag time. The blends of core and coating materials were evaluated for bulk density, tapped density, Hausner’s 
ratio, % Compressibility index and angle of repose. Compression coated tablets were evaluated for appearance, hardness, friability, weight 
variation, thickness and % drug release.  
Results: Core tablets, as well as compression coated tablets, showed acceptable Pharmaco technical properties. Optimized core tablets were 
disintegrated within 15s due to the effectiveness of super disintegrant, sodium starch glycolate. Dissolution studies of compression coated tablets in 
media with different pH (1.2, 6.8, and 7.4) showed that drug release could be modulated by changing the concentration of EudragitL100 and 
Eudragit S100. The optimized batch exhibited 80% drug release up to 6 h with a 4 h lag time. Stability study of the optimized formulation indicated 
no significant change in appearance, physical parameters, drug content and drug release profile at accelerated conditions for two months.  
Conclusion: compression coated tablet of ketoprofen was successfully developed to achieve burst drug release after specific lag time. 
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INTRODUCTION 
Oral route of drug administration is perhaps the most appealing 
route for the delivery of drugs. Of the various dosage forms 
administered orally, the tablet is one of the most preferred dosage 
forms because of its ease of manufacturing, convenience in 
administration, accurate dosing, better stability and tamperproof 
nature [1]. Chrono-modulated drug delivery is defined as the rapid 
and transient release of a certain amount of molecules within a short 
time period immediately after a predetermined off released period, 
i.e., lag time or these systems have a peculiar mechanism of 
delivering the drug rapidly and completely after a lag time, i.e., a 
period of no drug release. Such a release pattern is known as 
pulsatile release [2-7]. Chrono-therapeutics refers to a treatment 
method in which in vivo drug availability is timed to match the 
rhythms of disease in order to optimize therapeutic outcomes and 
minimize side effects. It is based on the observation that there is an 
interdependent relationship between the peak to trough rhythmic 
activity in disease symptoms & risk factors, pharmacological 
sensitivity and pharmacokinetics of many drugs [8]. 
Diseases, such as hypertension, asthma, peptic ulcer, arthritis, etc., 
follow the body's circadian rhythm. Many systems in the human 
body, such as cardiovascular, pulmonary, hepatic and renal systems 
show variation in their function throughout a typical day. They are 
naturally synchronized with the internal body clocks and are 
controlled by the sleep-wake cycle. Each body system exhibits a 
peak time of functionality that is in accordance with these 
rhythmical cycles. Similarly, disease states affect the function of 
some of these systems in the body and therefore, they too exhibit a 
peak time of activity within a circadian rhythm [9].  
The compression coated tablet is a tab-in-tab concept which consists 
of core tablet completely surrounded by the coating material. 
Compression coating is a dry coating concept which omits usage of 
solvent & heat. The composition of core tablet & coating material 
regulates drug release pattern from the system [10, 11]. 
Ketoprofen is used to treat rheumatoid arthritis. It is BCS 
(Biopharmaceutical Classification System) class II drug having a half-
life of 1-3 h. Patients with rheumatoid arthritis have severe pain 
early in the morning [12-14]. Hence, there is a need to formulate 
ketoprofen pulsatile release tablet to provide the highest drug level 
during early morning hours. Khadabadi S [15] and Rane AB [16] et 
al. formulated press coated tablet for pulsatile drug delivery of 
ketoprofen using HPMC and a combination of hydrophilic (glycine 
max husk or sodium alginate) and hydrophobic polymers 
(micronized ethyl cellulose powder), respectively. Fan TY et al. 
prepared pulsatile release tablets using a combination of 
ethylcellulose and Eudragit L as film coating materials and cross-
linked polyvinyl pyrrolidone (PVP) in the core tablets [17]. Pandey S 
et al. prepared “tablets in capsule” system for facilitating both 
immediate and pulsatile drug deliveries of theophylline to mimic the 
circadian rhythm of nocturnal asthma [18]. Aim of the present study 
was to achieve burst release of ketoprofen after specific lag time from 
compression coated tablets using Eudragit® polymers. Ketoprofen 
compression coated tablets having a combination of Eudragit L100 
and S100 to achieve pulsatile release has not been reported yet.  
MATERIALS AND METHODS 
Materials 
Ketoprofen was received as a gift sample from Neon Pharma, 
Mumbai, India. Eudragit L100, Eudragit S 100, microcrystalline 
cellulose, sodium starch glycolate, PVP K 30, talc and magnesium 
stearate was purchased from Balaji drugs, Surat, India. 
Methods  
Identification of ketoprofen 
Drug identification was performed using melting point, UV analysis and 
Fourier transform infrared spectroscopy (FTIR) study (Bruker Optics 
Alpha, Germany). An IR spectrum of the drug was recorded in the range 
of 4000-500 cm-1. Assay of ketoprofen was performed as per IP [19].  
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Bulk characterization of ketoprofen powder 
Ketoprofen powder was characterized by appearance, colour, odour, 
and particle size and flow property. Particle size determination by 
sieve analysis and flow property characterization by Hausner’s ratio, 
Carr’s index and angle of repose was performed as per USP [20]. 
Formulation of compression coated tablet 
Preparation of ketoprofen core tablets by direct compression 
method (batch P1
The composition of core tablet (batch P
) 
1
Preparation of ketoprofen core tablets by wet granulation 
method (batches P
) is mentioned in table 1. 
The drug and excipients were passed through sieve no. 40; mixed 
and compressed into tablets using a tablet machine (Rimek mini 
press 1) equipped with 6.5 mm diameter punch.  
2 to P6
The composition of core tablet (batch P
) 
2  to P6
  
) is mentioned table 
1. The drug and excipients (previously passed through sieve no. 
40) were mixed and granulated using PVP K30 solution as the 
granulating agent. The wet mass was passed through sieve no. 30 
and the granules were dried and compressed into tablets using a 
tablet machine (Rimek mini press 1) equipped with 6.5 mm 
diameter punch. 
Table 1: Compositions of core tablets of preliminary batches P1 to P
Formulation 
6 
 Batch P  Batch P1  Batch P2 Batch P3 Batch P4 Batch P5 6 
Drug (mg) 80 80 80 80 80 80 
Microcrystalline cellulose (mg) 58 58 58 58 58 58 
Sodium Starch Glycolate (mg) 6 6 6 6 6 6 
 Magnesium stearate (mg) 3 3 3 3 3 3 
Talc (mg) 3 3 3 3 3 3 
Polyvinyl pyrollidone K30 (mg) - 1 2 3 4 5 
 
Coating of core tablets using eudragit S100 (batch E1) 
The core tablets were coated using Eudragit S100 (batch E1) (10%) 
by the compression coating method. The complete compression 
coated tablet was prepared by placing 50% of the outer layer 
powder mixture in the die, manually centering the previously 
prepared core tablets on the powder in the die & loading the 
remaining 50% of the outer layer powder mixture into the die, the 
contents were then compressed using a single press tableting 
machine fitted with a 8 mm diameter concave punch set.  
Coating of core tablets using mixture of eudragit S100 and 
Eudragit L100 (batches F1 to F9
The core tablets were coated by compression method with different 
weight ratios of (% w/w) mixture of Eudragit S100 and Eudragit 
L100 (table 2). Agglomerates of a mixture of Eudragit S100 and 
Eudragit L100 were prepared using PVP K 30 (1%) as a binder. 
) 
Evaluation of powder blends and compression coated tablets 
Evaluation of Powder blends of core tablets and coating layer  
Micromeritics (angle of repose, bulk density, tapped density and 
percentage compressibility) of core and coat layer blends was 
determined prior to manufacturing of compression coated tablets [21]. 
Evaluation of core and compression coated tablets 
Core and compression coated tablets were characterized for 
appearance, diameter, thickness, weight variation, hardness, 
friability and % drug content. Hardness, thickness and friability 
were determined by the Monsanto hardness tester, digital vernier 
calipers and friabilator respectively. Disintegration test of core 
tablets was performed in a USP disintegration apparatus using three 
different mediums (0.1 N HCl (Hydrochloric acid), pH 4.6 acetate 
buffer, pH 7.4 phosphate buffer). 
  




F F1 F2 F3 F4 F5 F6 F7 F8 9 
Eudragit L100 20 20 20 40 40 40 60 60 60 
Eudragit S100 40 60 100 40 60 100 40 60 100 
Magnesium 
Stearate 
3 3 3 3 3 3 3 3 3 
Talc 2 2 2 2 2 2 2 2 2 
 
In vitro release of drug from compression coated tablets was 
determined using 6-station USP dissolution-basket apparatus (TDT-
06T, Electrolab) at 50 rpm at 37.0±0.5 °C. Dissolution of ketoprofen 
from compression coated tablet was monitored for 2 h in 900 ml 0.1 
N HCl followed by 900 ml pH 4.6 acetate buffer solutions for 4 h 
followed by 900 ml pH 7.4 phosphate buffers for 22 h.  
At predetermined time interval a 5 ml sample was withdrawn from 
each dissolution vent and replaced with fresh medium to maintain 
the sink condition. The samples withdrawn were filtered through 
Whatman filter paper and the drug content in each sample was 
analyzed by UV spectrophotometer after suitable dilution (UV-3092, 
Lab-India, India) at 260 nm. The dissolution test was performed in 
triplicate. Drug dissolved at specified time period was plotted as 
cumulative percent release versus time curve. The lag time of 
batches F1 to F9
Stability studies 
 were calculated based on drug release>10% 
Compression coated tablets of the optimized batch were packed in 
alu-blisters and stored at accelerated conditions (40 °C/75 % 
Relative humidity) for 3 mo and evaluated for appearance, hardness, 
% drug content and in vitro drug release at an interval of one month 
up to three months [22]. 
RESULTS AND DISCUSSION 
Identification of ketoprofen 
The melting point of the ketoprofen was found to be in the range of 
95-98 ºC, which complied with a standard reference. Identification 
peak of ketoprofen was present in the recorded UV spectrum at λ 
max 260 nm which complied with UV spectra of pure ketoprofen 
given in reference clerk [23]. IR spectra of ketoprofen showed a 
characteristic peak at 1693 cm-1 (C=O stretching), 1650 cm-1 (C=C 
stretching), 1281 cm-1
Bulk characterization of ketoprofen powder 
 (C-N stretching). FTIR spectrum of drug was 
comparable with reference FTIR spectrum (fig. 1) [19]. Percentage 
drug content was found to be 99.49±0.64 which complied with the 
limit provided in Indian pharmacopeia, 2010. 
Carr’s index, Hausner’s ratio and angle of repose of drug powder 
were 34.36%, 1.52 and 40.36°, respectively, which indicated a poor 
flow and compressibility of drug powder. 
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Fig. 1: FTIR spectra of a) reference ketoprofen as per IP and b) 
ketoprofen sample used for this study 
 
Formulation and evaluation of dosage forms 
Evaluation of powder blends of core tablets  
Carr’s index and Hausner’s ratio blend of batch P1 to P6 is mentioned 
in table 3. Blend of batch P1 exhibited poor flow property and 
compressibility of blend hence it was not suitable to prepare tablets 
by the direct compression method. Hence, wet granulation 
technique using PVP K 30 as a binder was employed to prepare core 
tablets. Powder blends of all batches (P2 to P6
Evaluation of core tablets of ketoprofen 
) indicated acceptable 
flow property and compressibility (table 3). Granulation process 
improved flow property and compressibility of the blend. Consiglieri 
VO et al. also proved that the production of granules of fluconazole 
with PVP improved flow and compressibility of fluconazole [24]. 
Patel et al. concluded that granulation could be an interesting 
method to improve the flow property of a poorly flowable Lactose 
Monohydrate when associated with a suitable binder and the 
granulation technique [25]. 
Results of parameters like weight variation, hardness, friability, 
Thickness and % drug content of core tablets are shown in table 4. 
All tablets were produced with an acceptable weight variation 
(<10%), uniform thickness, acceptable hardness (3-5 kg/cm2) and 
acceptable friability (<1%). Percentage drug content of all tablets 
was in the range of 95–105. All tablets were disintegrated within 2 
min due to the presence of super disintegrant sodium starch 
glycolate (table 5). Super disintegrant sodium starch glycolate 
absorbs water rapidly and swells in water to the extent of 200–
300% and exert sufficient pressure inside the tablets to break up 
into particles [26, 27]. Batch P2 exhibited faster disintegration 
among all the batches (P2 to P6) due to the minimum amount of 
binder in the formulation. Setty CM et al. compared acacia, PVP and 
starch paste as a binder in fast disintegrating tablets and concluded 
that PVP showed least disintegration time of tablets [28]. Binder 
Sharma D et al. also successfully developed fast disintegrating 
tablets using PVP and SSG as a binder-super disintegrant 
combination [26]. Tablets of batch P2
  
 were used for further studies 
to prepare compression coated tablets. 
Table 3: Results of evaluation of powder blend of core tablets of preliminary batches (P1 to P6
Parameter 
) 
P P1 P2 P3 P4 P5 6 
























Hausner’s ratio 1.95 1.14 1.19 1.19 1.17 1.17 






























P 4±0.5 2 0.410±0.010 150.05±0.66 2.1+0.05 98.8+0.45 
P 4±0.1 3 0.354±0.050 155.1±1.33 2.0+0.02 98.83+1.6 
P 4±0.3 4 0.423±0.011 149.9±0.66 2.1+0.01 99.07+0.94 
P 3.5±0.09 5 0.356±0.020 150.05±0.66 2.1+0.05 98.89+1.5 
P 5±0.4 6 0.349±0.021 151.05±2.66 2.1+0.04 100.66+1.8 
*mean±SD 
 
Table 5: Disintegration time of the core tablet of ketoprofen 
Batch Disintegration time in dissolution medium 
0.1 N HCl* (pH 1.2) (s) pH 6.8 Buffer*(s) pH 7.4 buffer*(s) 
P 33±1.9 2 17±1.5 15±3.3 
P 57±6.4 3 54±3.8 52±1.6 
P 59±4.3 4 58±6.2 60±4.5 
P 58±1.8 5 58±4.1 59±1.1 
P 60±8.1 6 118±3.5 120±4.5 
*mean (n=6)±SD 
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Coating of core tablets using eudragit S100 (Batch E1
Hausner’s ratio (1.32) and Carr’s index (24.24%) of the blend 
indicated good flowability and compressibility. Only 49% of the drug 
was released up to 8 h and lag time was 5 h. These clearly indicated 
that tablet coated with Eudragit S100 alone could provide 
satisfactory lag time but failed to provide complete drug release. 
Such release profile was not desirable, so the further study was 
performed in which combination of Eudragit S100 and Eudragit 
L100 was coated on core tablets. Cheng G et al. coated pellets with 
Eudragit S100 alone and observed that the dissolving process of the 
coating layer of S100 alone was rather slow, resulting in very slow 
drug release [29]. 
) Coating of core tablets using mixture of Eudragit S100 and 
Eudragit L 100 (batches F1-F9
Hausner’s ratio (1.45) and compressibility index (31.19%) of coating 
powder blend showed poor flow property and compressibility of the 
blend. A mixture of Eudragit S100 and L100 was granulated to 
improve flow property and compressibility of the blend.  
)  
Evaluation of compression coated tablets of batches F1 to F
Powder blends of batches F
9 
1 to F9 exhibited  
  
good flow characteristic 
(table 6). Core tablets, as well as compression coated tablets, showed 
acceptable Pharmaco-technical properties (table 7). 




F F1 F2 F3 F4 F5 F6 F7 F8 9 








































Hausner’s ratio 1.14 1.13 1.22 1.21 1.81 1.21 1.30 1.70 1.25 
 Carr’s index (%) 12.3 18.6 18.1 17.7 18.6 17.7 23.2 15.1 15.4 




















Not more than 10% of the drug was released in 0.1 N HCl due to the 
presence of Eudragit in the coating layer. Dangi P et al. [30] also stated 
that Eudragit prevented drug release in stomach pH. Less than 80% of 
the drug was released at 6 h in batches F1, F2 and F3; whereas batches 
F4 to F8 exhibited more than 80% drug release at 6 h (fig. 2 and 3).  
 
Fig. 2: Dissolution study of ketoprofen from compression coated 
tablets (n= 06) of batches of batches F1 to F5 for 2 h in 900 ml 
0.1 N HCl followed by 900 ml pH 4.6 acetate buffer solutions for 
4 h followed by 900 ml pH 7.4 phosphate buffer for 22 h 
 
 
Fig. 3: Dissolution study of ketoprofen from compression coated 
tablets (n= 6) of batches F6 to F9 for 2 h in 900 ml 0.1 N HCl 
followed by 900 ml pH 4.6 acetate buffer solutions for 4 h 
followed by 900 ml pH 7.4 phosphate buffer for 22 h 
Lower level of Eudragit L100 could not rovide a desirable burst drug 
release at 6 h. Among Batches F1, F2 and F3, F3 exhibited maximum 
lag time i.e. 4 h which indicated that as Eudragit S100 increases 
there is an increment in lag time. Mehta R et al. also supported the 
same findings [31]. Batches F4, F5 and F6 released more than 80% of 
the drug at 6 h and batch F6 exhibited maximum lag time. Batches 
F7, F8 and F9 could release more than 85% drug at 6 h but could not 
achieve desirable lag time.  
Most commonly used pH dependent coating polymers Eudragit 
L100 and Eudragit S100 which dissolve at pH 6.0 and 7.0, 
respectively. Since pH varies in the different parts of GT tract, if 
these two polymers are combined with each other at various 
ratios, it would be possible to achieve drug release within the pH 
range of 6.0-7.0 [32]. Hence, only batch F 6 could provide desirable 
attributes, i.e. more than 80% drug release at 6 h and 4 h lag time 
hence, Batch F6 was considered as optimized batch. Batch F 6 
exhibited maximum lag time i.e., 4 h which is considered to be 
ideal as indicated in fig. 4. 
 
 
Fig. 4: Mean Lag time (n=6) of compression coated tablets of 
batches F1 to F
Results of stability study of optimized batch indicated no significant 
change in appearance, physical parameters, and drug release profile 
at accelerated conditions for two months (table 8). 
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Table 7: Evaluation of core and compression coated tablets of batches F1 to F
Batch  
9 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
% Friability Compression coated  0.42± 0.35± 0.42± 0.35± 0.41± 0.42± 0.35± 0.41± 0.42± 
Tablets* 0.05 0.04 0.05 0.02 0.04 0.05 0.04 0.02 0.05 
Core  0.41± 0.35± 0.42± 0.35± 0.34± 0.35± 0.41± 0.35± 0.41± 
Tablets* 0.01 0.05 0.01 0.02 0.02 0.05 0.01 0.02 0.01 
Hardness (Kg/cm2 Compression coated  ) 6.2± 6.2± 5.3± 5.6± 5.9± 5.4± 6.2± 6.2± 5.7± 
Tablets* 0.07 0.11 0.09 0.04 0.05 0.05 0.07 0.01 0.04 
Core tablets* 04± 04± 04± 3.5± 05± 04± 04± 05± 3.5± 
0.1 0.1 0.1 0.09 0.4 0.1 0.1 0.4 0.9 
Thickness (mm) Compression coated  4.27± 4.22± 4.09± 4.17± 4.20± 4.2± 4.08± 4.16± 4.09± 
Tablets* 0.01 0.03 0.003 0.02 0.02 0.01 0.04 0.04 0.03 
Core  2.66± 2.00± 2.1± 2.66± 2.1± 2.1± 2.1± 2.1± 2.0± 
Tablets* 0.02 0.005 0.05 0.02 0.056 0.05 0.05 0.05 0.05 
Average weight (mg) Compression coated  250.02± 247.1±0 250.05± 249.9± 253± 250± 249± 250± 252± 
Tablets* 0.66 0.06 0.6 0.66 0.56 0.052 0.66 0.001 0.064 
Core  150.05± 152.1± 149.9± 155.05± 150.05± 149.9± 155.05± 151± 150.05± 
Tablets* 0.66 1.33 0.66 2.66 0.66 0.66 0.2.66 0.001 0.66 
 
Table 8: Results of stability study of ketoprofen compression coated tablet 





Lag time(h) Q6* 
Initial No change 5.4±0.05 0.42±0.05 4 83.26±0.60 
One month No change 5.3±0.05 0.42±0.05 4 81.61±0.98 
Two month No change 5.1±0.05 0.41±0.05 4 84.87±2.87 




The chrono therapeutic dosage form of ketoprofen was formulated 
by a compression coating technique which could provide the drug 
release in the early morning hours if the tablet is taken at late night. 
The concentration of Eudragit S 100 and Eudragit L100 can regulate 
lag time, whereas; the amount of super disintegrant in core tablet 
can regulate burst drug release. Optimized batch (F6
ACKNOWLEDGEMENT 
) consisted of a 
combination of Eudragit S100 and Eudragit L100 in a ratio of 100:40 
could release about 80-85% of the drug within 6 h with a lag time of 
4 h. Lag time can be improved from 4 h to 6 h for better patient 
compliance. Thus, pulsatile release of ketoprofen can be achieved 
from compression coated tablets using Eudragit® polymers.  
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